Lipoprotein metabolism and CKD: Overview

Clinical and Experimental Nephrology

Volumn 18, Issue 2, 2014, Pages 243-246

  Barter, Philip ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Chronic kidney disease; High density lipoproteins; Plasma lipoproteins; Triglyceride

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIGLYCERIDE RICH LIPOPROTEIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; CHYLOMICRON;

CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; DYSLIPIDEMIA; HUMAN; LIPID BLOOD LEVEL; LIPID TRANSPORT; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; REVIEW; BLOOD; CHRONIC KIDNEY FAILURE; METABOLISM;

CHYLOMICRONS; HUMANS; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; RENAL INSUFFICIENCY, CHRONIC;

EID: 84899931075     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-013-0866-9     Document Type: Review

References (20)

1. Attman PO, Samuelsson O. Dyslipidemia of kidney disease. Curr Opin Lipidol. 2009;20:293-9.
2. Kwan BC, Kronenberg F, Beddhu S, Cheung AK. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol. 2007;18:1246-61. (Pubitemid 46536911)
3. Rajman I, Harper L, McPake D, Kendall MJ, Wheeler DC. Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transpl. 1998;13:2281-7. (Pubitemid 28416554)
4. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis. 2000;35:852-62. (Pubitemid 30238197)
5. Kaysen GA. Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutr. 2009;19:73-7.
6. Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis. 1993;21:573-92. (Pubitemid 23178473)
7. Vaziri ND, Deng G, Liang K. Hepatic HDL receptor, SR-B1 and apo A-I expression in chronic renal failure. Nephrol Dial Transpl. 1999;14:1462-6. (Pubitemid 29241738)
8. Haffner SM, Gruber KK, Aldrete G Jr, Morales PA, Stern MP, Tuttle KR. Increased lipoprotein(a) concentrations in chronic renal failure. J Am Soc Nephrol. 1992;3:1156-62.
9. Bairaktari E, Elisaf M, Tsolas O, Siamopoulos KC. Serum Lp(a) levels in patients with moderate renal failure. Nephron. 1998;79:367-8. (Pubitemid 28310355)
10. Barter PJ, Nicholls SJ, Rye K-A, Anantharamaiah GM, Navab M, Fogelman AM. Anti-inflammatory properties of HDL. Circ Res. 2004;95:764-72.
11. Fryirs MA, Barter PJ, Appavaroo M, Tuch BE, Tabet F, Heather AK, Rye KA. Effects of high-density lipoproteins on pancreatic {beta}-cell insulin secretion. Arterioscler Thromb Vasc Biol. 2010;30:1642-8.
12. Vaziri ND, Liang K. Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int. 1996;50:1928-35. (Pubitemid 26417536)
13. Vaziri ND, Yuan J, Ni Z, Nicholas SB, Drew CR, Norris KC. Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression. Clin Exp Nephrol. 2012;16:238-43.
14. Mordasini R, Frey F, Flury W, Klose G, Greten H. Selective deficiency of hepatic triglyceride lipase in uremic patients. N Engl J Med. 1977;297:1362-6. (Pubitemid 8256293)
15. Vaziri ND, Liang K, Parks JS. Down-regulation of hepatic lecithin: cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int. 2001;59:2192-6. (Pubitemid 32467611)
16. Guarnieri GF, Moracchiello M, Campanacci L, et al. Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia. Kidney Int Suppl. 1978;(8):S26-30.
17. Kimura H, Miyazaki R, Imura T, et al. Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels. Kidney Int. 2003;64:1829-37.
18. Dirican M, Akca R, Sarandol E, Dilek K. Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol. 2004;17:813-8. (Pubitemid 41158301)
19. Liberopoulos EN, Papavasiliou E, Miltiadous GA, et al. Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis. Perit Dial Int. 2004;24:580-9. (Pubitemid 39562063)
20. Nobecourt E, Davies MJ, Brown BE, Curtiss LK, Bonnet DJ, Charlton F, Januszewski AS, Jenkins AJ, Barter PJ, Rye KA. The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia. 2007;50:643-53. (Pubitemid 46215509)